Humoral response to COVID-19 infection in immunosuppressed patients with inflammatory bowel disease.

Authors:
Scharrer S; Kutschera M; Weseslindtner L; Primas C; Vogelsang H.

Journal:
Eur J Gastroenterol Hepatol

Publication Year: 2021

DOI:
10.1097/MEG.0000000000002094

PMCID:
PMC7846249

PMID:
33522752

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Eur J Gastroenterol Hepatol

Abbreviation: Eur J Gastroenterol Hepatol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A nomogram for analyzing risk factors of poor treatment response in patients with autoimmune hepati…
Wang X; Liu H; Wang P and 3 more (2024) - Transparency Score: 3/6
AST to ALT ratio as a prospective risk predictor for liver cirrhosis in patients with chronic HBV i…
Lai X; Chen H; Dong X and 7 more (2024) - Transparency Score: 3/6
Construction and validation of the predictive model for gallbladder cancer liver metastasis patient…
Zhang W; Chen Z; Sa B. (2024) - Transparency Score: 3/6
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn's dise…
D'Haens G; Baert F; Danese S and 8 more (2024) - Transparency Score: 3/6
Management advice for patients with reflux-like symptoms: an evidence-based consensus.
Hungin AP; Yadlapati R; Anastasiou F and 8 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
1/6
0.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Acknowledgements: Conflicts of interest: C.P. has served as a speaker/consultant/advisory board member for AbbVie, MSD, Takeda, Janssen, Merck, Ferring and Astro Pharma. H.V. has served as a speaker/consultant/advisory board member for AbbVie, Amgen, Gilead, MSD, Takeda, Janssen, Merck, Ferring, Astro Pharma, Pfizer, Roche, Sandoz, Panaceo, Covidien, Falk Pharma GmbH, and Montavit. SS, MK, and LW have nothing to disclose."

Funding Disclosure
Protocol Registration
Open Access
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025